Thanks to the huge profit of 53 percent since begin this year it's one of the best shares of the biotech sector.
Returns stock Sartorius over several periods, excluding dividend returns
Investors who invested in 2007 in the company's share now have a huge profit of 3609 percent. Since 2012 the stock has a price gain of 510 percent. over the past 90 days the stock made a loss of 14 percent.
On average the sector trades costs now 3 times the earnings per share. Currently the sector trades at 18,88 times the book value per share. Since 2012 the sector has a profit of 216 percent and since 2007 a higher of 405 percent.
Over the current book year the total revenue will be 1,71 billion euros (consensus estimates). This is slightly more than 2018's revenue of 1,57 billion euros.
The analysts expect for 2019 a net profit of 190 million euros. For this year the consensus of the result per share is a profit of 2,85 euros. With this the price/earnings-ratio is an extreme 51,4.
Analysts expect a dividend of 0,62 cents per share. Sartorius's dividend yield thus equals 0,42 percent. The average dividend yield of the biotech companies is an attractive 8 percent.
Sartorius's market capitalization is based on the number of outstanding shares around 5,01 billion euros. The Sartorius stock was the past 12 months quite volatile. Since last October the stock is even 27 percent higher. This year the stock price moved between 90 and 179 euro.
Click here for dividend . At 17.35 the stock trades 1,03 percent higher at 146,5 euros.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.